Abstract:Background: ARID1A is a gene that produces a protein called BAF250a, which is a component of the chromatin remodeling complex. This complex plays a critical role in regulating gene expression by altering the structure of chromatin. ARID1A mutations and MSI-H are mutually exclusive in endometrial cancer, but not in ovarian cancer. ARID1A mutations are associated with high TMB in certain types of cancer, such as endometrial and gastric cancer. The relationship between ARID1B mutations and MSI-H/TMB is complex, and this study aims to clarify it in gastric cancer. Methods: The formalin-fixed paraffin-embedded (FFPE) tissues 337 patients with gastric cancer who have underwent next-generation sequencing (NGS) include 733 genes from Nov, 2019 to Mar, 2023 in 3DMed Clinical Laboratory Inc. were investigated in this study. These patients are still being followed up. Result: In this study, 337 patients with gastric cancer were analyzed for ARID1A and ARID1B mutations, MSI-H status, and TMB levels. The results showed that 17.8% of the patients had ARID1A mutations, 8.9% had ARID1B mutations, and 3.6% had both mutations. Additionally, 7.7% of the all patients had MSI-H. The study found that patients with ARID1 mutations had significantly higher rates of MSI-H compared to unselected patients. Specifically, 35% of patients with ARID1A mutations, 30% with ARID1B mutations, and 75% with both mutations had MSI-H, compared to 7.7% in unselected patients. Furthermore, TMB levels were higher in patients with ARID1A or ARID1B mutations compared to wild-type and unselected patients (p<0.0001). There was no significant difference observed between patients with ARID1A and ARID1B mutation subgroups in terms of TMB levels (p = 0.3515). However, TMB levels were lower in patients with ARID1A or ARID1B mutations compared to patients with both mutations (p = 0.0036, p = 0.0104). These findings suggest that ARID1 mutations may cause genomic and chromosomal instability in gastric cancer, leading to higher rates of MSI-H and TMB. Conclusion: The study highlights the potential clinical significance of ARID1 mutations as a biomarker for predicting MSI-H and TMB levels in gastric cancer, which could help guide personalized treatment strategies for patients with this disease. However, further research is needed to confirm these findings and to determine the clinical implications of ARID1 mutations in gastric cancer. Citation Format: Chunsheng Xu, Bo Lian, Yujie Dai, Weiming Duan, Feilong Zhao, Mengbin Li. ARID1 mutations may serve as a predictor of MSI and TMB levels in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3639.

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy

The effects of ARID1A mutation in gastric cancer and its significance for treatment

Clinical Outcome and Molecular Landscape of Patients with ARID1A-loss Gastric Cancer.

Abstract 1179: A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response

ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study

ARID1A is a Coactivator of STAT5 that Contributes to CD8+ T Cell Dysfunction and Anti-PD-1 Resistance in Gastric Cancer

Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.

Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities

ARID1A is involved in DNA double-strand break repair in gastric cancer

Uncovering the Dosage-Dependent Roles of Arid1a in Gastric Tumorigenesis for Combinatorial Drug Therapy

Chromatin Remodeling Gene AT-rich Interactive Domain-Containing Protein 1A Suppresses Gastric Cancer Cell Proliferation by Targeting PIK3CA and PDK1.

Loss of ARID1A Expression is Associated with Systemic Inflammation Markers and Has Important Prognostic Significance in Gastric Cancer

Pan-cancer Analysis of ARID1A Alterations As Biomarkers for Immunotherapy Outcomes

The Landscape of ARID1A Variants and Correlation with Tumor Mutational Burden in Chinese Solid Tumor Patients.

ASF1b is a Novel Prognostic Predictor Associated with Cell Cycle Signaling Pathway in Gastric Cancer

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.

Abstract 3639: ARID1 mutations may serve as a predictor of MSI and TMB levels in gastric cancer

Abstract 3221: Targeting ARID1A-mutated gastric cancer cells with synthetic lethal approaches

Prognostic role of ARID1A negative expression in gastric cancer

Loss of ARID1A Expression is Associated with Poor Prognosis in Patients with Gastric Cancer.